

SÅ,awomir Åawicki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/836079/publications.pdf>

Version: 2024-02-01

47
papers

706
citations

567281

15
h-index

642732

23
g-index

53
all docs

53
docs citations

53
times ranked

921
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma Concentrations of Matrilysins MMP-7 and MMP-26 as Diagnostic Biomarkers in Breast Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 1436.	2.4	12
2	Prenatal Screening of Trisomy 21: Could Oxidative Stress Markers Play a Role?. <i>Journal of Clinical Medicine</i> , 2021, 10, 2382.	2.4	6
3	Serum Chemerin Concentration Is Associated with Proinflammatory Status in Chronic Coronary Syndrome. <i>Biomolecules</i> , 2021, 11, 1149.	4.0	7
4	Novel Approaches to an Integrated Route for Trisomy 21 Evaluation. <i>Biomolecules</i> , 2021, 11, 1328.	4.0	3
5	Plasma Levels and Diagnostic Utility of VEGF in a Three-Year Follow-Up of Patients with Breast Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 5452.	2.4	7
6	Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis. <i>Pathology and Oncology Research</i> , 2020, 26, 791-800.	1.9	15
7	Possible Diagnostic Application of CXCL12 and CXCR4 as Tumor Markers in Breast Cancer Patients. <i>Anticancer Research</i> , 2020, 40, 3221-3229.	1.1	8
8	The Significance of Apolipoprotein E Measurement in the Screening of Fetal Down Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 3995.	2.4	7
9	<p>Matrilysins and Stromelysins in Pathogenesis and Diagnostics of Cancers</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 10949-10964.	1.9	16
10	Can VEGFR-3 be a better tumor marker for breast cancer than CA 15-3?. <i>Acta Biochimica Polonica</i> , 2020, 67, 25-29.	0.5	3
11	Search of reference biomarkers reflecting orbital tissue remodeling in the course of Gravesâ€™ orbitopathy. <i>Folia Histochemica Et Cytobiologica</i> , 2020, 58, 37-45.	1.5	5
12	Plasma Level of MMP-10 May Be a Prognostic Marker in Early Stages of Breast Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 4122.	2.4	5
13	C-C motif chemokine ligand 5 and C-C chemokine receptor typeâ€™5: possible diagnostic application in breast cancer patients. <i>Acta Biochimica Polonica</i> , 2020, 67, 539-449.	0.5	2
14	Plasma Levels and Tissue Expression of Selected Cytokines, Metalloproteinases and Tissue Inhibitors in Patients With Cervical Cancer. <i>Anticancer Research</i> , 2019, 39, 6403-6412.	1.1	10
15	Diagnostic Power of Selected Cytokines, MMPs and TIMPs in Ovarian Cancer Patients â€™ ROC Analysis. <i>Anticancer Research</i> , 2019, 39, 2575-2582.	1.1	8
16	Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers. <i>BMC Cancer</i> , 2019, 19, 398.	2.6	15
17	Levels of Selected Matrix Metalloproteinases, Their Inhibitors in Saliva, and Oral Status in Juvenile Idiopathic Arthritis Patients vs. Healthy Controls. <i>BioMed Research International</i> , 2019, 2019, 1-9.	1.9	8
18	Diagnostic power of VEGF, MMP-9 and TIMP-1 in patients with breast cancer. A multivariate statistical analysis with ROC curve. <i>Advances in Medical Sciences</i> , 2019, 64, 1-8.	2.1	16

#	ARTICLE	IF	CITATIONS
19	Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor - VEGFR-2 and Applicability of these Parameters as Tumor Markers in the Diagnostics of Breast Cancer. <i>Pathology and Oncology Research</i> , 2019, 25, 1477-1486.	1.9	10
20	First-trimester irisin and fetuin-A concentration in predicting macrosomia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2019, 32, 2868-2873.	1.5	7
21	ROC analysis of selected matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in psoriatic patients. <i>Postepy Dermatologii I Alergologii</i> , 2018, 35, 167-173.	0.9	7
22	Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients. <i>BioMed Research International</i> , 2018, 2018, 1-9.	1.9	27
23	Plasma levels and diagnostic utility of macrophage-colony stimulating factor, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 as tumor markers in cervical cancer patients. <i>Tumor Biology</i> , 2018, 40, 101042831879036.	1.8	10
24	Human Plasma Levels of Vascular Endothelial Growth Factor, Matrix Metalloproteinase 9, and Tissue Inhibitor of Matrix Metalloproteinase 1 and Their Applicability as Tumor Markers in Diagnoses of Cervical Cancer Based on ROC Analysis. <i>Cancer Control</i> , 2018, 25, 107327481878935.	1.8	10
25	Plasma levels of VEGF-A, VEGF B, and VEGFR-1 and applicability of these parameters as tumor markers in diagnosis of breast cancer. <i>Acta Biochimica Polonica</i> , 2018, 65, 621-628.	0.5	8
26	Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers. <i>Journal of Ovarian Research</i> , 2017, 10, 39.	3.0	14
27	Unstimulated salivary flow, pH, proteins and oral health in patients with Juvenile Idiopathic Arthritis. <i>BMC Oral Health</i> , 2017, 17, 94.	2.3	26
28	Plasma levels and diagnostic utility of VEGF, MMP-2 and TIMP-2 in the diagnostics of breast cancer patients. <i>Biomarkers</i> , 2017, 22, 157-164.	1.9	22
29	Influence of narrowband ultraviolet-B phototherapy on plasma concentration of matrix metalloproteinase-12 in psoriatic patients. <i>Postepy Dermatologii I Alergologii</i> , 2017, 4, 328-333.	0.9	3
30	Narrowband ultraviolet B light treatment changes plasma concentrations of MMP-3, MMP-9 and TIMP-3 in psoriatic patients. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 575-582.	2.0	4
31	Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 911.	2.0	42
32	Therapy of psoriasis with narrowband ultraviolet-B light influences plasma concentrations of MMP-2 and TIMP-2 in patients. <i>Therapeutics and Clinical Risk Management</i> , 2016, Volume 12, 1579-1585.	2.0	6
33	Diagnostic Power of Vascular Endothelial Growth Factor and Macrophage Colony-Stimulating Factor in Breast Cancer Patients Based on ROC Analysis. <i>Mediators of Inflammation</i> , 2016, 2016, 1-8.	3.0	18
34	Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer. <i>Annals of Laboratory Medicine</i> , 2016, 36, 223-229.	2.5	25
35	Plasma Levels and Diagnostic Utility of M-CSF, MMP-2 and its Inhibitor TIMP-2 in the Diagnostics of Breast Cancer Patients. <i>Clinical Laboratory</i> , 2016, 62, 1661-1669.	0.5	7
36	MMP-2 i MMP-9 jako czynniki prognostyczne w udarze niedokrwiennym mÅ³zgu. <i>Aktualnosci Neurologiczne</i> , 2016, 16, 125-130.	0.1	0

#	ARTICLE	IF	CITATIONS
37	M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients. <i>Journal of Ovarian Research</i> , 2015, 8, 27.	3.0	22
38	Reference values for placental growth factor (PIGF) concentration and uterine artery Doppler pulsatility index (PI) at 11-13+6 weeks of gestation in the Polish population. <i>Ginekologia Polska</i> , 2014, 85, 488-93.	0.7	7
39	The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors. <i>Journal of Ovarian Research</i> , 2013, 6, 45.	3.0	49
40	Hematopoietic cytokines as tumor markers in breast malignancies. A multivariate analysis with ROC curve in breast cancer patients. <i>Advances in Medical Sciences</i> , 2013, 58, 207-215.	2.1	16
41	VEGF, M-CSF and CA 15-3 as a new tumor marker panel in breast malignancies: a multivariate analysis with ROC curve. <i>Growth Factors</i> , 2013, 31, 98-105.	1.7	14
42	Plasma Levels of IL-17, VEGF, and Adrenomedullin and S-Cone Dysfunction of the Retina in Children and Adolescents without Signs of Retinopathy and with Varied Duration of Diabetes. <i>Mediators of Inflammation</i> , 2013, 2013, 1-8.	3.0	17
43	Hematopoietic cytokines as tumor markers in gynecological malignancies: A multivariate analysis with ROC curve in endometrial cancer patients. <i>Growth Factors</i> , 2012, 30, 29-36.	1.7	14
44	Hematopoietic cytokines as tumor markers in gynecological malignancies. A multivariate analysis in epithelial ovarian cancer patients. <i>Growth Factors</i> , 2012, 30, 357-366.	1.7	16
45	Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients. <i>Folia Histochemica Et Cytobiologica</i> , 2012, 50, 213-219.	1.5	13
46	Could Neutrophil-Gelatinase-Associated Lipocalin and Cystatin C Predict the Development of Contrast-Induced Nephropathy after Percutaneous Coronary Interventions in Patients with Stable Angina and Normal Serum Creatinine Values?. <i>Kidney and Blood Pressure Research</i> , 2007, 30, 408-415.	2.0	98
47	The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients. <i>Clinica Chimica Acta</i> , 2006, 371, 112-116.	1.1	23